This is a preview of subscription content
Subscription info for Chinese customers
We have a dedicated website for our Chinese customers. Please go to naturechina.com to subscribe to this journal.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Janjigian, Y. Y. et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature 600, 727–730 (2021)
About this article
Cite this article
Hindson, J. KEYNOTE-811: pembrolizumab in advanced HER2+ gastric cancer. Nat Rev Gastroenterol Hepatol 19, 79 (2022). https://doi.org/10.1038/s41575-022-00577-y